{"id":"W4319915130","doi":"10.1016/j.msard.2023.104561","title":"Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Medicine; Natalizumab; Dosing; Expanded Disability Status Scale; Physical therapy; Multiple sclerosis; Rating scale; Randomized controlled trial; Clinical trial; Internal medicine; Clinical endpoint; Progressive multifocal leukoencephalopathy; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001471218,0.0006910689,0.003515555,0.0004899427,0.0006491837,0.0001185883,0.0001496628,0.0006013455,0.00002553894],"category_scores_gemma":[0.009097072,0.0005194973,0.0009213252,0.0006800793,0.000711704,0.0002249523,0.0001920455,0.0006296592,0.000005978685],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006156588,"about_ca_system_score_gemma":0.0001321439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001145922,"about_ca_topic_score_gemma":0.0001454968,"domain_scores_codex":[0.9937826,0.0006760222,0.003035918,0.001142945,0.0006026558,0.0007598078],"domain_scores_gemma":[0.9880949,0.009173215,0.001427624,0.0005637024,0.0002696083,0.000470927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6817317,0.01430745,0.1235256,0.000219983,0.01838141,0.00007002939,0.02016614,0.0004715319,0.01205148,0.00001352319,0.0003480913,0.128713],"study_design_scores_gemma":[0.8101828,0.002260007,0.153509,0.001448485,0.004923145,0.000002984369,0.01240803,0.0144035,0.0001905541,0.00003806608,0.00002970689,0.0006037195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836448,0.006985613,0.00005425871,0.0002669535,0.001659599,0.006820349,0.0001123717,0.000382978,0.0000730114],"genre_scores_gemma":[0.9951618,0.003743533,0.0003012414,0.00007536532,0.00005237396,0.000292012,0.0001999382,0.0001398314,0.0000339379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1284511,"threshold_uncertainty_score":0.9997256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08653767171726767,"score_gpt":0.302707932638336,"score_spread":0.2161702609210683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}